Good morning, everyone, and welcome to another working week. And nice to see you again after an extended weekend respite on the side of the pond. The time flew by, did it not? We enjoyed special time with a couple of our short people and hope that you also had a chance to indulge your own priorities. Now, though, the time has come to return to the usual routines of meetings, deadlines and the like. So here are some tidbits. Hope your day goes well and do keep in touch …

IQWiG, the independent authority in Germany that evaluates new drugs, criticized a lack of data directly comparing  new immunotherapies for treating bladder cancer because doctors could be overwhelmed or misled by available information, Reuters reports. The agency wants regulations changed so that companies are required to conduct head-to-head studies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy